Biogen’s Skyclarys is on course to becoming the first approved medicine for the inherited neurological disease Friedreich’s ataxia (FA) in the EU after it was recommended
InDex Pharmaceuticals has said it will abandon a phase 3 trial of its lead drug cobitolimod in moderate-to-severe ulcerative colitis, its only clinical-stage programme, wr
Galapagos has signed a deal to jettison its troubled JAK inhibitor drug Jyseleca, agreeing to sell the rights to rheumatoid arthritis and ulcerative colitis therapy to Ita
After an earlier rejection, the FDA has approved Eli Lilly’s first-in-class IL-23p19 inhibitor mirikizumab as a treatment for adults with moderately to severely active ulc
Pfizer has said it will shed staff and cut its operating costs by around $3.5 billion, as it faces a shortfall in COVID-19 vaccine and treatment sales, with revenues now e
In its second pipeline-boosting deal in two days, Sanofi has pledged €469 million (around $490 million) upfront for rights to an anti-TL1A therapy being developed by Teva